Sinonasal cancer: whole-exome sequencing reveals potential therapeutic targets
Results from a study suggest that some existing inhibitors may benefit all subtypes of these rare malignancies, which currently lack effective treatments
Promising results for an FGFR 1–3 inhibitor in molecularly altered tumours
CPL304110 shows acceptable toxicity and early signs of activity in heavily pre-treated patients with advanced solid malignancies
Test for gut microbiota predicts survival in patients receiving an immune checkpoint inhibitor
An easy-to-use method to detect dysbiosis may help guide selection of cancer treatments and microbiota-centred interventions
Combining liquid biopsy technologies may help improve tumour monitoring
Results from two studies suggest that this approach is essential to refining liquid biopsy use in early cancer detection and to check tumour progression
Should cancer therapy be tailored based on receptor tyrosine kinase alterations?
Data from a molecular analysis of receptor tyrosine kinase-mutated cancers show a wide heterogeneity of alterations and response to tyrosine kinase inhibitor monotherapy
Dynamic immunoediting of tumours may hold the clue to effective treatment with immunotherapy
Success of immunotherapy is tied to tumour evolution from early- to late-stages, as a study in non-small-cell lung cancer highlights
Molecular cancer early detection and prevention - an attainable goal?
Adoption of molecular-based early detection techniques in clinical practice depends on the success of large-scale clinical studies and cost barriers
Improving the efficacy of engineered T-cells – from gene transfer to genome editing
A new level of sophistication, namely genome editing, is now available to help overcome previous hurdles with adoptive T-cell therapies
New targets for off-the-shelf treatments open up the field of precision immunotherapy
The identification of mutation-derived neoantigens may help elicit antitumour immune responses in patients with cancer, but this approach is challenging
Liquid biopsy moving to early cancer detection: is it still early times?
Despite the promises shown by some innovative technologies in the studies presented, they will not replace existing diagnostic modalities soon